Australia markets closed
  • ALL ORDS

    7,325.80
    +8.30 (+0.11%)
     
  • ASX 200

    7,063.50
    +4.90 (+0.07%)
     
  • AUD/USD

    0.7740
    -0.0015 (-0.19%)
     
  • OIL

    63.07
    -0.39 (-0.61%)
     
  • GOLD

    1,777.30
    +10.50 (+0.59%)
     
  • BTC-AUD

    79,226.48
    -1,190.29 (-1.48%)
     
  • CMC Crypto 200

    1,398.97
    +7.26 (+0.52%)
     
  • AUD/EUR

    0.6455
    -0.0018 (-0.28%)
     
  • AUD/NZD

    1.0825
    +0.0019 (+0.17%)
     
  • NZX 50

    12,684.73
    +48.18 (+0.38%)
     
  • NASDAQ

    14,041.91
    +15.71 (+0.11%)
     
  • FTSE

    7,019.53
    +36.03 (+0.52%)
     
  • Dow Jones

    34,200.67
    +164.68 (+0.48%)
     
  • DAX

    15,459.75
    +204.42 (+1.34%)
     
  • Hang Seng

    28,969.71
    +176.57 (+0.61%)
     
  • NIKKEI 225

    29,683.37
    +40.68 (+0.14%)
     

Vir Biotechnology and GlaxoSmithKline Expand Their COVID Partnership to Flu

Brian Orelli, PhD and Keith Speights, The Motley Fool
·3-min read

Last year, Vir Biotechnology (NASDAQ: VIR) and GlaxoSmithKline (NYSE: GSK) partnered up to develop Vir's coronavirus antibody treatment. The London-based pharma must have liked what it saw in Vir, because GlaxoSmithKline recently signed on to develop more drugs developed by Vir. In this video from Motley Fool Live, recorded on Feb. 22, Fool.com contributors Brian Orelli and Keith Speights discuss the deal, which covers treatments and preventions for the flu and other viral infections, and what it means for Vir's future.